Patents by Inventor Douglas R. Savage

Douglas R. Savage has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220088278
    Abstract: The present invention relates generally to an endoprosthesis for maintaining patency of a body vessel, e.g., a stent, in a basically tubular configuration comprised of a structural lattice with a mesh covering which is capable of storing releasing one or more drugs to and penetrating into surrounding tissue.
    Type: Application
    Filed: January 28, 2020
    Publication date: March 24, 2022
    Inventors: Ronald E. Betts, Douglas R. Savage
  • Patent number: 10456508
    Abstract: An improvement in drug-eluting stents, and method of their making, are disclosed. The surface of a metal stent is roughened to have a surface roughness of at least about 20 ?in (0.5 ?m) and a surface roughness range of between about 300-700 ?in (7.5-17.5 ?m). The roughened stent surface is covered with a polymer-free coating of a limus drug, to a coating thickness greater than the range of surface roughness of the roughened stent surface.
    Type: Grant
    Filed: January 13, 2017
    Date of Patent: October 29, 2019
    Assignee: Biosensors International Group, Ltd.
    Inventors: Douglas R. Savage, John E. Shulze, Ronald E. Betts, Sepehr Fariabi, Shih-Horng Su
  • Publication number: 20170128635
    Abstract: An improvement in drug-eluting stents, and method of their making, are disclosed. The surface of a metal stent is roughened to have a surface roughness of at least about 20 ?in (0.5 ?m) and a surface roughness range of between about 300-700 ?in (7.5-17.5 ?m). The roughened stent surface is covered with a polymer-free coating of a limus drug, to a coating thickness greater than the range of surface roughness of the roughened stent surface.
    Type: Application
    Filed: January 13, 2017
    Publication date: May 11, 2017
    Inventors: Douglas R. Savage, John E. Shulze, Ronald E. Betts, Sepehr Fariabi, Shih-Horng Su
  • Publication number: 20170095358
    Abstract: The invention is related to a biodegradable stent for vascular placement comprising, a tubular biodegradable metal structure, a biodegradable organic layer covering the surfaces of the structure, and optionally a biodegradable polymer coating covering the organic surface layer. The organic layer is a derivative of a monomer vapor injected plasma and is applied in a plasma enhanced chemical vapor deposition process. Thereby the biodegradable organic layer is an organosilane layer and the biodegradable polymer coating contains a therapeutic drug.
    Type: Application
    Filed: June 24, 2015
    Publication date: April 6, 2017
    Inventors: Douglas R. Savage, John Dang Nguyen
  • Patent number: 9579424
    Abstract: An improvement in drug-eluting stents, and method of their making, are disclosed. The surface of a metal stent is roughened to have a surface roughness of at least about 20 ?in (0.5 ?m) and a surface roughness range of between about 300-700 ?in (7.5-17.5 ?m). The roughened stent surface is covered with a polymer-free coating of a limus drug, to a coating thickness greater than the range of surface roughness of the roughened stent surface.
    Type: Grant
    Filed: July 20, 2012
    Date of Patent: February 28, 2017
    Assignee: Biosensors International Group, Ltd.
    Inventors: Douglas R. Savage, John E. Shulze, Ronald E. Betts, Sepehr Fariabi, Shih-Horng Su
  • Patent number: 8871292
    Abstract: A radially expandable, endovascular stent designed for placement at a site of vascular injury, for inhibiting restenosis at the site, a method of using, and a method of making the stent. The stent includes a radially expandable body formed of one or more metallic filaments and a liquid-infusible mechanical anchoring layer attached to or formed in outer surface of the filaments. A drug coating in the stent is composed of a substantially polymer-free composition of an anti-restenosis drug, and has a substratum infused in the anchoring layer and a substantially continuous surface stratum of drug that is brought into direct contact with the vessel walls at the vascular site. Thus, the rate of release of the anti-restenosis drug from the surface stratum into said vascular site is determined solely by the composition of said drug coating.
    Type: Grant
    Filed: July 24, 2012
    Date of Patent: October 28, 2014
    Assignee: Biosensors International Group, Ltd.
    Inventors: Douglas R. Savage, Ronald E. Betts
  • Publication number: 20140200654
    Abstract: An intravascular stent and method for inhibiting restenosis, following vascular injury, is disclosed. The stent has an expandable, linked-filament body and a drug-release coating formed on the stent-body filaments, for contacting the vessel injury site when the stent is placed in-situ in an expanded condition. The coating releases, for a period of at least 4 weeks, a restenosis-inhibiting amount of a monocyclic triene immunosuppressive compound having an alkyl group substituent at carbon position 40 in the compound. The stent, when used to treat a vascular injury, gives good protection against clinical restenosis, even when the extent of vascular injury involves vessel overstretching by more than 30% diameter. Also disclosed is a stent having a drug-release coating composed of (i) 10 and 60 weight percent poly-dl-lactide polymer substrate and (ii) 40-90 weight percent of an anti-restenosis compound, and a polymer undercoat having a thickness of between 1-5 microns.
    Type: Application
    Filed: March 18, 2014
    Publication date: July 17, 2014
    Applicant: Biosensors International Group, Ltd.
    Inventors: John E. Shulze, Ronald E. Betts, Douglas R. Savage
  • Patent number: 8715341
    Abstract: An intravascular stent and method for inhibiting restenosis, following vascular injury, is disclosed. The stent has an expandable, linked-filament body and a drug-release coating formed on the stent-body filaments, for contacting the vessel injury site when the stent is placed in-situ in an expanded condition. The coating releases, for a period of at least 4 weeks, a restenosis-inhibiting amount of a monocyclic triene immunosuppressive compound having an alkyl group substituent at carbon position 40 in the compound. The stent, when used to treat a vascular injury, gives good protection against clinical restenosis, even when the extent of vascular injury involves vessel overstretching by more than 30% diameter. Also disclosed is a stent having a drug-release coating composed of (i) 10 and 60 weight percent poly-dl-Iactide polymer substrate and (ii) 40-90 weight percent of an anti-restenosis compound, and a polymer undercoat having a thickness of between 1-5 microns.
    Type: Grant
    Filed: October 9, 2012
    Date of Patent: May 6, 2014
    Assignee: Biosensors International Group, Ltd.
    Inventors: John E. Shulze, Ronald E. Betts, Douglas R. Savage
  • Patent number: 8545550
    Abstract: An intravascular stent and method for inhibiting restenosis, following vascular injury, is disclosed. The stent has an expandable, linked-filament body and a drug-release coating formed on the stent-body filaments, for contacting the vessel injury site when the stent is placed in-situ in an expanded condition. The coating releases, for a period of at least 4 weeks, a restenosis-inhibiting amount of the macrocyclic triene immunosuppressive compound everolimus. The stent, when used to treat a vascular injury, gives good protection against clinical restenosis, even when the extent of vascular injury involves vessel overstretching by more than 30% diameter. Also disclosed is a stent having a drug-release coating composed of (i) 10 and 60 weight percent poly-dl-lactide polymer substrate and (ii) 40-90 weight percent of an anti-restenosis compound, and a polymer undercoat having a thickness of between 1-5 microns.
    Type: Grant
    Filed: July 24, 2012
    Date of Patent: October 1, 2013
    Assignee: Biosensors International Group, Ltd.
    Inventors: John E. Shulze, Ronald E. Betts, Douglas R. Savage
  • Publication number: 20130035754
    Abstract: An intravascular stent and method for inhibiting restenosis, following vascular injury, is disclosed. The stent has an expandable, linked-filament body and a drug-release coating formed on the stent-body filaments, for contacting the vessel injury site when the stent is placed in-situ in an expanded condition. The coating releases, for a period of at least 4 weeks, a restenosis-inhibiting amount of a monocyclic triene immunosuppressive compound having an alkyl group substituent at carbon position 40 in the compound. The stent, when used to treat a vascular injury, gives good protection against clinical restenosis, even when the extent of vascular injury involves vessel overstretching by more than 30% diameter. Also disclosed is a stent having a drug-release coating composed of (i) 10 and 60 weight percent poly-dl-Iactide polymer substrate and (ii) 40-90 weight percent of an anti-restenosis compound, and a polymer undercoat having a thickness of between 1-5 microns.
    Type: Application
    Filed: October 9, 2012
    Publication date: February 7, 2013
    Applicant: Biosensors International Group, Ltd.
    Inventors: John E. SHULZE, Ronald E. BETTS, Douglas R. SAVAGE
  • Publication number: 20130006350
    Abstract: An intravascular stent and method for inhibiting restenosis, following vascular injury, is disclosed. The stent has an expandable, linked-filament body and a drug-release coating formed on the stent-body filaments, for contacting the vessel injury site when the stent is placed in-situ in an expanded condition. The coating releases, for a period of at least 4 weeks, a restenosis-inhibiting amount of the macrocyclic triene immunosuppressive compound everolimus. The stent, when used to treat a vascular injury, gives good protection against clinical restenosis, even when the extent of vascular injury involves vessel overstretching by more than 30% diameter. Also disclosed is a stent having a drug-release coating composed of (i) 10 and 60 weight percent poly-dl-lactide polymer substrate and (ii) 40-90 weight percent of an anti-restenosis compound, and a polymer undercoat having a thickness of between 1-5 microns.
    Type: Application
    Filed: July 24, 2012
    Publication date: January 3, 2013
    Applicant: Biosensors International Group, Ltd.
    Inventors: John E. Shulze, Ronald E. Betts, Douglas R. Savage
  • Publication number: 20120330406
    Abstract: An improvement in drug-eluting stents, and method of their making, are disclosed. The surface of a metal stent is roughened to have a surface roughness of at least about 20 ?in (0.5 ?m) and a surface roughness range of between about 300-700 ?in (7.5-17.5 ?m). The roughened stent surface is covered with a polymer-free coating of a limus drug, to a coating thickness greater than the range of surface roughness of the roughened stent surface.
    Type: Application
    Filed: July 20, 2012
    Publication date: December 27, 2012
    Applicant: Biosensors International Group, Ltd.
    Inventors: Douglas R. Savage, John E. Shulze, Ronald E. Betts, Sepehr Fariabi, Shih-Horng Su
  • Publication number: 20120290076
    Abstract: A radially expandable, endovascular stent designed for placement at a site of vascular injury, for inhibiting restenosis at the site, a method of using, and a method of making the stent. The stent includes a radially expandable body formed of one or more metallic filaments and a liquid-infusible mechanical anchoring layer attached to or formed in outer surface of the filaments. A drug coating in the stent is composed of a substantially polymer-free composition of an anti-restenosis drug, and has a substratum infused in the anchoring layer and a substantially continuous surface stratum of drug that is brought into direct contact with the vessel walls at the vascular site. Thus, the rate of release of the anti-restenosis drug from the surface stratum into said vascular site is determined solely by the composition of said drug coating.
    Type: Application
    Filed: July 24, 2012
    Publication date: November 15, 2012
    Applicant: Biosensors International Group, Ltd.
    Inventors: Douglas R. SAVAGE, Ronald E. BETTS
  • Patent number: 8308795
    Abstract: An intravascular stent and method for inhibiting restenosis, following vascular injury, is disclosed. The stent has an expandable, linked-filament body and a drug-release coating formed on the stent-body filaments, for contacting the vessel injury site when the stent is placed in-situ in an expanded condition. The coating releases, for a period of at least 4 weeks, a restenosis-inhibiting amount of a monocyclic triene immunosuppressive compound having an alkyl group substituent at carbon position 40 in the compound. The stent, when used to treat a vascular injury, gives good protection against clinical restenosis, even when the extent of vascular injury involves vessel overstretching by more than 30% diameter. Also disclosed is a stent having a drug-release coating composed of (i) 10 and 60 weight percent poly-dl-lactide polymer substrate and (ii) 40-90 weight percent of an anti-restenosis compound, and a polymer undercoat having a thickness of between 1-5 microns.
    Type: Grant
    Filed: January 29, 2010
    Date of Patent: November 13, 2012
    Assignee: Biosensors International Group, Ltd.
    Inventors: John E. Shulze, Ronald E. Betts, Douglas R. Savage
  • Patent number: 8252047
    Abstract: A radially expandable, endovascular stent designed for placement at a site of vascular injury, for inhibiting restenosis at the site, a method of using, and a method of making the stent. The stent includes a radially expandable body formed of one or more metallic filaments and a liquid-infusible mechanical anchoring layer attached to or formed in outer surface of the filaments. A drug coating in the stent is composed of a substantially polymer-free composition of an anti-restenosis drug, and has a substratum infused in the anchoring layer and a substantially continuous surface stratum of drug that is brought into direct contact with the vessel walls at the vascular site. Thus, the rate of release of the anti-restenosis drug from the surface stratum into said vascular site is determined solely by the composition of said drug coating.
    Type: Grant
    Filed: February 8, 2011
    Date of Patent: August 28, 2012
    Assignee: Biosensors International Group, Ltd.
    Inventors: Douglas R. Savage, Ronald E. Betts
  • Patent number: 8252046
    Abstract: An intravascular stent and method for inhibiting restenosis, following vascular injury, is disclosed. The stent has an expandable, linked-filament body and a drug-release coating formed on the stent-body filaments, for contacting the vessel injury site when the stent is placed in-situ in an expanded condition. The coating releases, for a period of at least 4 weeks, a restenosis-inhibiting amount of the macrocyclic triene immunosuppressive compound everolimus. The stent, when used to treat a vascular injury, gives good protection against clinical restenosis, even when the extent of vascular injury involves vessel overstretching by more than 30% diameter. Also disclosed is a stent having a drug-release coating composed of (i) 10 and 60 weight percent poly-dl-lactide polymer substrate and (ii) 40-90 weight percent of an anti-restenosis compound, and a polymer undercoat having a thickness of between 1-5 microns.
    Type: Grant
    Filed: December 15, 2009
    Date of Patent: August 28, 2012
    Assignee: Biosensors International Group, Ltd.
    Inventors: John E. Shulze, Ronald E. Betts, Douglas R. Savage
  • Publication number: 20120029626
    Abstract: A radially expandable, endovascular stent designed for placement at a site of vascular injury, for inhibiting restenosis at the site, a method of using, and a method of making the stent. The stent includes a radially expandable body formed of one or more metallic filaments where at least one surface of the filaments has a roughened or abraded surface. The stent may include a therapeutic agent on the abraded surface.
    Type: Application
    Filed: August 10, 2011
    Publication date: February 2, 2012
    Applicant: Biosensors International Group
    Inventors: Douglas R. Savage, John E. Schulze, Ronald E. Betts, Sepehr Fariabi, Shih-Horng Su
  • Patent number: 8067055
    Abstract: A radially expandable, endovascular stent designed for placement at a site of vascular injury, for inhibiting restenosis at the site, a method of using, and a method of making the stent. The stent includes a radially expandable body formed of one or more metallic filaments where at least one surface of the filaments has a roughened or abraded surface. The stent may include a therapeutic agent on the abraded surface.
    Type: Grant
    Filed: March 23, 2007
    Date of Patent: November 29, 2011
    Assignee: Biosensors International Group, Ltd.
    Inventors: Douglas R. Savage, John E. Shulze, Ronald E. Betts, Sepehr Fariabi, Shih-Horng Su
  • Publication number: 20110123704
    Abstract: A radially expandable, endovascular stent designed for placement at a site of vascular injury, for inhibiting restenosis at the site, a method of using, and a method of making the stent. The stent includes a radially expandable body formed of one or more metallic filaments and a liquid-infusible mechanical anchoring layer attached to or formed in outer surface of the filaments. A drug coating in the stent is composed of a substantially polymer-free composition of an anti-restenosis drug, and has a substratum infused in the anchoring layer and a substantially continuous surface stratum of drug that is brought into direct contact with the vessel walls at the vascular site. Thus, the rate of release of the anti-restenosis drug from the surface stratum into said vascular site is determined solely by the composition of said drug coating.
    Type: Application
    Filed: February 8, 2011
    Publication date: May 26, 2011
    Applicant: Biosensors International Group, Ltd.
    Inventors: Douglas R. Savage, Ronald E. Betts
  • Patent number: 7901451
    Abstract: A radially expandable, endovascular stent designed for placement at a site of vascular injury, for inhibiting restenosis at the site, a method of using, and a method of making the stent. The stent includes a radially expandable body formed of one or more metallic filaments and a liquid-infusible mechanical anchoring layer attached to or formed in outer surface of the filaments. A drug coating in the stent is composed of a substantially polymer-free composition of an anti-restenosis drug, and has a substratum infused in the anchoring layer and a substantially continuous surface stratum of drug that is brought into direct contact with the vessel walls at the vascular site. Thus, the rate of release of the anti-restenosis drug from the surface stratum into said vascular site is determined solely by the composition of said drug coating.
    Type: Grant
    Filed: September 22, 2005
    Date of Patent: March 8, 2011
    Assignee: Biosensors International Group, Ltd.
    Inventors: Douglas R. Savage, Ronald E. Betts, John E. Shulze